Global Microbiome Modulator Market
市场规模（十亿美元）
CAGR :
% 
USD
3.16 Billion
USD
8.57 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 3.16 Billion |
 Market Size (Forecast Year) |
USD 8.57 Billion |
 CAGR |
% |
| Major Markets Players |
|
全球微生物組調節劑市場，副產品（益生元、乳霜、益生菌、藥物等）、應用（消化健康、免疫健康、口腔健康等）、最終用戶（醫院、專科診所等）、分銷管道（醫院藥房、零售藥房等）——行業趨勢及預測（至 2032 年）
微生物組調節劑市場分析
微生物群 是指生活在皮膚、唾液和胃腸道（GIT）中的一類微生物。細菌、古細菌和真菌都屬於微生物群。微生物群有助於執行某些對人體健康有益的任務。
微生物組調節劑市場規模
2024 年全球微生物組調節劑市場規模為 31.6 億美元，預計到 2032 年將達到 85.7 億美元，2025 年至 2032 年預測期內的複合年增長率為 13.30%。
報告範圍和市場細分
|
屬性 |
微生物組調節劑關鍵市場洞察 |
|
分割 |
|
|
覆蓋國家 |
北美洲的美國、加拿大和墨西哥、德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其、歐洲的其他地區、中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓、亞太地區（APAC）的其他地區、沙烏地阿拉伯、阿聯酋、南非、埃及、以色列、中東和非洲（MEA）的其他地區（MEA）的其他地區。 |
|
主要市場參與者 |
賽諾菲、寶潔、拜耳、帝斯曼、杜邦、養樂多本社、BioGaia AB、Probi AB、科漢森控股 A/S、Ingredion Incorporated、Immuron Ltd、Pharmavite、MICROBIOME THERAPEUTICS, LLC、大塚美國製藥、Quorum Innovations、 |
微生物組調節劑市場動態
驅動程式
- 生活方式障礙
慢性健康和生活方式疾病患者發病率的飆升直接推動了對有效醫療治療的需求。這意味著高血壓、心臟病、癌症、阿茲海默症、氣喘、慢性肝病、糖尿病和骨質疏鬆症的盛行率上升將增加對微生物組調節劑的需求。
- 增加醫療基礎建設投資
影響市場成長率的另一個重要因素是醫療支出的持續成長，這有助於改善其基礎設施。醫療保健產業的成長和擴張，尤其是在發展中經濟體，將促進新興和先進的醫療技術、設備和藥物的使用和應用。這將直接增加對微生物組調節劑治療的需求。
- 研究與開發活動
公共和私人市場參與者之間策略合作的日益增多，正在推動研發活動數量的日益增長。這些研發成果正應用於新型藥物和醫療技術領域，這將推動微生物組調節劑治療的需求。
此外，公共和私人組織不斷加強宣傳力度，老年人口不斷增加，以及對副作用較小的預防藥物的需求增加，這些都將推動市場成長率。其他因素，例如對有效療法的需求增加、經濟實惠藥物的供應增加以及早期診斷程序的採用率不斷提高，也將對市場成長率產生正面影響。
機會
個人可支配收入水準的提高，以及發展中經濟體對治療方案可用性認識的不斷增強，將進一步創造豐厚的市場成長機會。全球醫療旅遊業的蓬勃發展、市場參與者之間合作的增加、主要參與者在產品開發中的參與度不斷提高，以及尚未開發的市場的巨大成長潛力，都將創造充足的市場成長機會。
限制/挑戰
然而，研發成本高昂以及缺乏有效治療方法，限制了創新藥物的應用範圍，將成為市場發展的最大限制因素之一。欠發達和落後經濟體缺乏認知和必要的基礎設施，政府對生物相似藥審批的嚴格監管，以及新冠疫情帶來的不利條件，將進一步阻礙市場的成長。藥物和抑制劑審批速度緩慢、未滿足的醫療需求以及專利到期案例的增多，也將對市場的成長速度構成挑戰。
本微生物組調節劑市場報告詳細介紹了最新發展動態、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內和本地市場參與者的影響，並分析了新興收入來源、市場法規變化、戰略市場增長分析、市場規模、品類市場增長、應用領域和市場主導地位、產品審批、產品發布、地域擴張以及市場技術創新等方面的機遇。如需了解更多關於微生物組調節劑市場的信息，請聯繫 Data Bridge 市場研究部門獲取 分析師簡報，我們的團隊將幫助您做出明智的市場決策，實現市場成長。
微生物組調節劑市場範圍
微生物組調節劑市場根據產品、應用、最終用戶和分銷管道進行細分。這些細分市場的成長將幫助您分析行業中成長緩慢的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
產品
- 益生元
- 乳霜
- 益生菌
- 藥物
- 其他的
應用
- 消化健康
- 免疫健康
- 口腔健康
- 其他的
最終用戶
- 醫院
- 專科診所
- 其他的
分銷管道
- 醫院藥房
- 零售藥局
- 其他的
微生物組調節劑市場區域分析
對微生物組調節劑市場進行了分析，並按國家、產品、應用、最終用戶和分銷管道提供了市場規模洞察和趨勢，如上所述。
微生物組調節劑市場報告涵蓋的國家包括北美洲的美國、加拿大和墨西哥、歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其、歐洲其他地區、中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓、亞太地區（APAC）的其他地區、沙烏地阿拉伯、阿拉伯聯合、南非、澳洲、南美洲的其他
北美在微生物組調節劑市場的市場份額和市場收入方面佔據主導地位，並將在預測期內繼續保持其主導地位。這得益於該地區主要參與者的存在、完善的醫療基礎設施、直腸炎發病率的上升以及優惠的報銷政策。另一方面，由於發展中國家對直腸炎的認識不斷提高以及政府支持力度的加大，預計亞太地區將在預測期內呈現最高增長率。
報告的國家部分還提供了各個市場的影響因素以及國內市場法規的變化，這些變化會影響市場的當前和未來趨勢。新銷售、替代銷售、國家人口統計、疾病流行病學和進出口關稅等數據點是預測各國市場狀況的一些主要指標。此外，在對國家/地區數據進行預測分析時，還考慮了全球品牌的存在和可用性、它們因來自本地和國內品牌的激烈或稀缺競爭而面臨的挑戰以及銷售管道的影響。
微生物組調節劑市場份額
微生物組調節劑市場競爭格局提供了按競爭對手劃分的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投入、新市場計劃、全球佈局、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度以及應用主導地位。以上提供的數據僅與公司在微生物組調節劑市場的重點相關。
微生物組調節劑市場領導者包括：
- 賽諾菲、寶潔
- 拜耳公司
- 帝斯曼
- 杜邦。
- 養樂多本社株式會社
- BioGaia公司
- Probi AB，Chr
- 漢森控股公司
- 英瑞安公司
- 伊穆隆有限公司
- 法瑪維特
- 微生物組治療有限公司
- 大塚美國製藥公司
- Quorum創新
- 默克夏普和多姆公司
- Symbiotix 生物療法公司
- 里特製藥公司
微生物組調節劑市場的最新發展
- 2020年，美國Vedanta Biosciences公司獲得美國生物醫學高級研究與發展管理局（BARDA）740萬美元資助，用於推進VE303治療高風險艱難梭菌感染（CDI）的臨床開發。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MICROBIOME MODULATOR MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MICROBIOME MODULATOR MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 SALES VOLUME
2.2.11 EPIDEMIOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MICROBIOME MODULATOR MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR MICROBIOME MODULATOR MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE MICROBIOME MODULATOR MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE MICROBIOME MODULATOR MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE MICROBIOME MODULATOR MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR MICROBIOME MODULATOR MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL MICROBIOME MODULATOR MARKET, BY PRODUCT TYPE
14.1 OVERVIEW
14.2 PREBIOTICS
14.2.1 BY TYPE
14.2.1.1. MANNAN-OLIGOSACCHARIDES
14.2.1.2. GALACTOOLIGOSACCHARIDES
14.2.1.3. FRUCTO-OLIGOSACCHARIDE
14.2.1.4. POLYDEXTROSE
14.2.1.5. OTHERS
14.2.2 BY CATEGORY
14.2.2.1. CONVENTIONAL
14.2.2.2. ORGANIC
14.2.3 BY SOURCE
14.2.3.1. PLANT-BASED
14.2.3.2. ANIMAL BASED
14.2.3.3. OTHERS (IF ANY)
14.2.4 BY PRODUCT TYPE
14.2.4.1. ORIGINAL
14.2.4.2. BLENDED
14.2.5 OTHERS
14.3 PROBIOTICS
14.3.1 BY TYPE
14.3.1.1. PROBIOTIC DIETARY SUPPLEMENTS
14.3.1.2. PROBIOTIC DAIRY YOGHURT
14.3.1.3. YOGHURT DRINKS
14.3.1.4. PROBIOTIC NON-DAIRY FOOD AND BEVERAGE
14.3.2 BY CATEGORY
14.3.2.1. CONVENTIONAL
14.3.2.2. ORGANIC
14.3.3 BY SOURCE
14.3.3.1. PLANT-BASED
14.3.3.2. ANIMAL BASED
14.3.3.3. OTHERS (IF ANY)
14.3.4 BY PRODUCT TYPE
14.3.4.1. ORIGINAL
14.3.4.2. BLENDED
14.3.5 OTHERS
14.4 SYNBIOTICS
14.4.1 BY TYPE
14.4.1.1. SYNBIOTIC SUPPLEMENTS
14.4.1.2. SYNBIOTIC FUNCTIONAL FOODS AND BEVERAGES
14.4.1.3. SYNBIOTIC FOODS FOR SPECIFIC CONDITIONS
14.4.1.4. OTHERS
14.4.2 BY CATEGORY
14.4.2.1. CONVENTIONAL
14.4.2.2. ORGANIC
14.4.3 BY SOURCE
14.4.3.1. PLANT-BASED
14.4.3.2. ANIMAL BASED
14.4.3.3. OTHERS (IF ANY)
14.4.4 BY PRODUCT TYPE
14.4.4.1. ORIGINAL
14.4.4.2. BLENDED
14.4.5 OTHERS
14.5 METAPROBIOTICS
14.5.1 BY TYPE
14.5.1.1. SUPPLEMENTS
14.5.1.2. FUNCTIONAL FOODS
14.5.1.3. BEVERAGES
14.5.1.4. OTHERS
14.5.2 BY CATEGORY
14.5.2.1. CONVENTIONAL
14.5.2.2. ORGANIC
14.5.3 BY SOURCE
14.5.3.1. PLANT-BASED
14.5.3.2. ANIMAL BASED
14.5.3.3. OTHERS (IF ANY)
14.5.4 BY PRODUCT TYPE
14.5.4.1. ORIGINAL
14.5.4.2. BLENDED
14.5.5 OTHERS
14.6 DRUGS/THERAPIES
14.6.1 FECAL MICROBIOTA TRANSPLANTATION (FMT)
14.6.1.1. REBYOTA
14.6.1.2. VOWST
14.6.1.3. FINCH THERAPEUTICS' FIN-524
14.6.1.4. OTHERS
14.6.2 PROBIOTIC DRUGS
14.6.2.1. VSL 3
14.6.2.2. FLORASTOR
14.6.2.3. ALIGN
14.6.2.4. OTHERS
14.6.3 ANTIBIOTIC-BASED MICROBIOME MODULATORS
14.6.3.1. INTESTINAL MICROFLORA MODULATOR (RIFAXIMIN):
14.6.3.2. XIFAXAN
14.6.3.3. OTHERS
14.6.4 OTHERS
14.7 OTHERS
14.7.1 PHYTOBIOTICS
14.7.2 POSTBIOTICS
14.7.3 OTHER MODULATORS
15 GLOBAL MICROBIOME MODULATOR MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 CAPSULES
15.2.3 POWDER
15.2.4 SOLUTIONS
15.2.5 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENEOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
15.4 TOPICAL
15.5 OTHERS
16 GLOBAL MICROBIOME MODULATOR MARKET, BY POPULATION TYPE
16.1 MALE
16.1.1 PEDIATRIC
16.1.2 ADULT
16.1.3 GERIATRIC
16.2 FEMALE
16.2.1 PEDIATRIC
16.2.2 ADULT
16.2.3 GERIATRIC
17 GLOBAL MICROBIOME MODULATOR MARKET, BY APPLICATION
17.1 OVERVIEW
17.2 ORAL HEALTH
17.3 SKIN HEALTH
17.4 IMMUNE HEALTH
17.5 DIGESTIVE HEALTH
17.6 METABOLIC HEALTH
17.7 OTHERS
18 GLOBAL MICROBIOME MODULATOR MARKET, BY END USER
18.1 OVERVIEW
18.2 HOSPITALS
18.2.1 BY TYPE
18.2.1.1. PUBLIC
18.2.1.2. PRIVATE
18.2.2 BY LEVEL
18.2.2.1. TIER 1
18.2.2.2. TIER 2
18.2.2.3. TIER 3
18.3 SPECIALTY CLINICS
18.3.1 PUBLIC
18.3.2 PRIVATE
18.4 HOME HEALTHCARE
18.5 ACADEMIC AND RESEARCH INSTITUTES
18.6 OTHERS
19 GLOBAL MICROBIOME MODULATOR MARKET, BY DISTRIBUTION CHANNEL
19.1 OVERVIEW
19.2 DIRECT TENDER
19.3 RETAIL SALES
19.3.1 OFFLINES SALES
19.3.1.1. HOSPITAL PHARMACIES
19.3.1.2. RETAIL PHARMACIES
19.3.1.3. OTHERS
19.3.2 ONLINE SALES
19.3.2.1. E-STORES
19.3.2.2. COMPANY WEBSITE
19.3.2.3. OTHERS
19.4 OTHERS
20 GLOBAL MICROBIOME MODULATOR MARKET, BY GEOGRAPHY
GLOBAL MICROBIOME MODULATOR MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS
REPRESENTED IN THIS CHAPTER BY COUNTRY)
20.1 NORTH AMERICA
20.1.1 U.S.
20.1.2 CANADA
20.1.3 MEXICO
20.2 EUROPE
20.2.1 GERMANY
20.2.2 FRANCE
20.2.3 U.K.
20.2.4 HUNGARY
20.2.5 LITHUANIA
20.2.6 AUSTRIA
20.2.7 IRELAND
20.2.8 NORWAY
20.2.9 POLAND
20.2.10 ITALY
20.2.11 SPAIN
20.2.12 RUSSIA
20.2.13 TURKEY
20.2.14 NETHERLANDS
20.2.15 SWITZERLAND
20.2.16 REST OF EUROPE
20.3 ASIA-PACIFIC
20.3.1 JAPAN
20.3.2 CHINA
20.3.3 TAIWAN
20.3.4 SOUTH KOREA
20.3.5 INDIA
20.3.6 AUSTRALIA
20.3.7 SINGAPORE
20.3.8 THAILAND
20.3.9 MALAYSIA
20.3.10 INDONESIA
20.3.11 PHILIPPINES
20.3.12 VIETNAM
20.3.13 REST OF ASIA-PACIFIC
20.4 SOUTH AMERICA
20.4.1 BRAZIL
20.4.2 ECUADOR
20.4.3 CHILE
20.4.4 COLOMBIA
20.4.5 VENEZUELA
20.4.6 ARGENTINA
20.4.7 PERU
20.4.8 CURAÇAO
20.4.9 PARAGUAY
20.4.10 URUGUAY
20.4.11 TRINIDAD AND TOBAGO
20.4.12 REST OF SOUTH AMERICA
20.5 MIDDLE EAST AND AFRICA
20.5.1 SOUTH AFRICA
20.5.2 SAUDI ARABIA
20.5.3 UAE
20.5.4 EGYPT
20.5.5 KUWAIT
20.5.6 ISRAEL
20.5.7 BOLIVIA
20.5.8 REST OF MIDDLE EAST AND AFRICA
20.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
21 GLOBAL MICROBIOME MODULATOR MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL MICROBIOME MODULATOR MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL MICROBIOME MODULATOR MARKET, COMPANY PROFILE
23.1 PROBI AB
23.1.1 COMPANY OVERVIEW
23.1.2 REVENUE ANALYSIS
23.1.3 GEOGRAPHIC PRESENCE
23.1.4 PRODUCT PORTFOLIO
23.1.5 RECENT DEVELOPMENTS
23.2 IMMURON LTD.
23.2.1 COMPANY OVERVIEW
23.2.2 REVENUE ANALYSIS
23.2.3 GEOGRAPHIC PRESENCE
23.2.4 PRODUCT PORTFOLIO
23.2.5 RECENT DEVELOPMENTS
23.3 BIOGAIA
23.3.1 COMPANY OVERVIEW
23.3.2 REVENUE ANALYSIS
23.3.3 GEOGRAPHIC PRESENCE
23.3.4 PRODUCT PORTFOLIO
23.3.5 RECENT DEVELOPMENTS
23.4 BAYERS AG
23.4.1 COMPANY OVERVIEW
23.4.2 REVENUE ANALYSIS
23.4.3 GEOGRAPHIC PRESENCE
23.4.4 PRODUCT PORTFOLIO
23.4.5 RECENT DEVELOPMENTS
23.5 POSTBIOTIC
23.5.1 COMPANY OVERVIEW
23.5.2 REVENUE ANALYSIS
23.5.3 GEOGRAPHIC PRESENCE
23.5.4 PRODUCT PORTFOLIO
23.5.5 RECENT DEVELOPMENTS
23.6 SANOFI
23.6.1 COMPANY OVERVIEW
23.6.2 REVENUE ANALYSIS
23.6.3 GEOGRAPHIC PRESENCE
23.6.4 PRODUCT PORTFOLIO
23.6.5 RECENT DEVELOPMENTS
23.7 PROCTER & GAMBLE
23.7.1 COMPANY OVERVIEW
23.7.2 REVENUE ANALYSIS
23.7.3 GEOGRAPHIC PRESENCE
23.7.4 PRODUCT PORTFOLIO
23.7.5 RECENT DEVELOPMENTS
23.8 DSM-FIRMENICH
23.8.1 COMPANY OVERVIEW
23.8.2 REVENUE ANALYSIS
23.8.3 GEOGRAPHIC PRESENCE
23.8.4 PRODUCT PORTFOLIO
23.8.5 RECENT DEVELOPMENTS
23.9 DUPONT
23.9.1 COMPANY OVERVIEW
23.9.2 REVENUE ANALYSIS
23.9.3 GEOGRAPHIC PRESENCE
23.9.4 PRODUCT PORTFOLIO
23.9.5 RECENT DEVELOPMENTS
23.1 YAKULT HONSHA CO., LTD.
23.10.1 COMPANY OVERVIEW
23.10.2 REVENUE ANALYSIS
23.10.3 GEOGRAPHIC PRESENCE
23.10.4 PRODUCT PORTFOLIO
23.10.5 RECENT DEVELOPMENTS
23.11 INGREDION
23.11.1 COMPANY OVERVIEW
23.11.2 REVENUE ANALYSIS
23.11.3 GEOGRAPHIC PRESENCE
23.11.4 PRODUCT PORTFOLIO
23.11.5 RECENT DEVELOPMENTS
23.12 SYNLOGICS
23.12.1 COMPANY OVERVIEW
23.12.2 REVENUE ANALYSIS
23.12.3 GEOGRAPHIC PRESENCE
23.12.4 PRODUCT PORTFOLIO
23.12.5 RECENT DEVELOPMENTS
23.13 SERES THERAPEUTICS
23.13.1 COMPANY OVERVIEW
23.13.2 REVENUE ANALYSIS
23.13.3 GEOGRAPHIC PRESENCE
23.13.4 PRODUCT PORTFOLIO
23.13.5 RECENT DEVELOPMENTS
23.14 MICROBIOTICA
23.14.1 COMPANY OVERVIEW
23.14.2 REVENUE ANALYSIS
23.14.3 GEOGRAPHIC PRESENCE
23.14.4 PRODUCT PORTFOLIO
23.14.5 RECENT DEVELOPMENTS
23.15 REBIOTIX INC. (FERRING)
23.15.1 COMPANY OVERVIEW
23.15.2 REVENUE ANALYSIS
23.15.3 GEOGRAPHIC PRESENCE
23.15.4 PRODUCT PORTFOLIO
23.15.5 RECENT DEVELOPMENTS
23.16 VEDANTA BIOSCIENCES, INC
23.16.1 COMPANY OVERVIEW
23.16.2 REVENUE ANALYSIS
23.16.3 GEOGRAPHIC PRESENCE
23.16.4 PRODUCT PORTFOLIO
23.16.5 RECENT DEVELOPMENTS
23.17 SIOLTA THERAPEUTICS
23.17.1 COMPANY OVERVIEW
23.17.2 REVENUE ANALYSIS
23.17.3 GEOGRAPHIC PRESENCE
23.17.4 PRODUCT PORTFOLIO
23.17.5 RECENT DEVELOPMENTS
23.18 KANVAS BIOSCIENCES
23.18.1 COMPANY OVERVIEW
23.18.2 REVENUE ANALYSIS
23.18.3 GEOGRAPHIC PRESENCE
23.18.4 PRODUCT PORTFOLIO
23.18.5 RECENT DEVELOPMENTS
23.19 MICROBIOME THERAPEUTICS INNOVATION GROUP
23.19.1 COMPANY OVERVIEW
23.19.2 REVENUE ANALYSIS
23.19.3 GEOGRAPHIC PRESENCE
23.19.4 PRODUCT PORTFOLIO
23.19.5 RECENT DEVELOPMENTS
23.2 AZITRA
23.20.1 COMPANY OVERVIEW
23.20.2 REVENUE ANALYSIS
23.20.3 GEOGRAPHIC PRESENCE
23.20.4 PRODUCT PORTFOLIO
23.20.5 RECENT DEVELOPMENTS
23.21 CHR. HANSEN HOLDING A/S
23.21.1 COMPANY OVERVIEW
23.21.2 REVENUE ANALYSIS
23.21.3 GEOGRAPHIC PRESENCE
23.21.4 PRODUCT PORTFOLIO
23.21.5 RECENT DEVELOPMENTS
23.22 RITTER PHARMACEUTICALS
23.22.1 COMPANY OVERVIEW
23.22.2 REVENUE ANALYSIS
23.22.3 GEOGRAPHIC PRESENCE
23.22.4 PRODUCT PORTFOLIO
23.22.5 RECENT DEVELOPMENTS
23.23 PHARMAVITE
23.23.1 COMPANY OVERVIEW
23.23.2 REVENUE ANALYSIS
23.23.3 GEOGRAPHIC PRESENCE
23.23.4 PRODUCT PORTFOLIO
23.23.5 RECENT DEVELOPMENTS
23.24 SYMBIOTIX BIOTHERAPIES, INC.
23.24.1 COMPANY OVERVIEW
23.24.2 REVENUE ANALYSIS
23.24.3 GEOGRAPHIC PRESENCE
23.24.4 PRODUCT PORTFOLIO
23.24.5 RECENT DEVELOPMENTS
23.25 MICROBIOTICA
23.25.1 COMPANY OVERVIEW
23.25.2 REVENUE ANALYSIS
23.25.3 GEOGRAPHIC PRESENCE
23.25.4 PRODUCT PORTFOLIO
23.25.5 RECENT DEVELOPMENTS
23.26 QUORUM INNOVATIONS
23.26.1 COMPANY OVERVIEW
23.26.2 REVENUE ANALYSIS
23.26.3 GEOGRAPHIC PRESENCE
23.26.4 PRODUCT PORTFOLIO
23.26.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
24 RELATED REPORTS
25 QUESTIONNAIRE
26 CONCLUSION
27 ABOUT DATA BRIDGE MARKET RESEARCH
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
